Bone metastases radiopharmaceuticals: an overview.

Vincenzo Cuccurullo, Giuseppe Lucio Cascini, Oscar Tamburrini, Antonio Rotondo, Luigi Mansi

Journal: Current radiopharmaceuticals 2013;6(1):41-7

PMID: 23470032

Abstract

The skeleton is one of the preferential sites for metastases of solid tumors, and metastatic disease is the most common malignancy of the bone. Diagnosis and evaluation of skeletal metastases require more frequently a combined approach of different diagnostic methods. Between the currently available imaging modalities, a major role is devoted to two radionuclide functional techniques namely scintigraphy and positron emission tomography (PET) imaging. Both these techniques require the use of different radiopharmaceuticals. The aim of this paper is to review the most important radiocompounds that can be successfully used to detect and/or characterize bone metastases.

Address: Department of Radiological Sciences - Second University of Naples, Naples, Italy.

DOI: 10.2174/1874471011306010007